GlassScriptPhysician profile
John A Schroth
NPI 1154406924
$1,213.79
in general payments reported to CMS, 2019-2025
24 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $317 · 2023: $164 · 2024: $158 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.38 | 2021-2025 | |
| Tactile Systems Technology INC | $120.31 | 2025 | Flexitouch Plus, Nimbl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $79.69 | 2021-2025 | Arexvy, Shingrix |
| Pfizer INC. | $66.49 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $58.82 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $49.95 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $41.92 | 2022-2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.33 | 2022 | |
| Lilly USA, LLC | $34.34 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $29.25 | 2023-2025 | |
| Astellas Pharma US INC | $27.51 | 2022 | |
| Stryker Corporation | $27.24 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Verona Pharma, INC. | $23.74 | 2025 | Ohtuvayre |
| Medtronic, INC. | $21.52 | 2025 | Intellis Adaptivestim |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.91 | 2023 | Cologuard Collection Kit |
| Opko Pharmaceuticals, LLC | $19.46 | 2023 | Rayaldee |
| Boston Scientific Corporation | $16.98 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $14.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.77 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.35 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.30 | 2024 | Voquezna |
| Amarin Pharma, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.